Tenofovir Disoproxil Fumarate/Inarigivir soproxil

N/A

Report date: 2025/03/18 17:01:50

Base Information

Drug NameTenofovir Disoproxil Fumarate/Inarigivir soproxil
Drug Alias NameSB-9200/tenofovir disoproxil fumarateSB-9225SB-11399
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRetinoic acid-inducible gene I stimulantsReverse transcriptase inhibitorsNucleotide-binding oligomerization domain-containing protein 2 stimulants
TargetsReverse transcriptaseNucleotide-binding oligomerization domain-containing protein 2Retinoic acid-inducible gene I
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Inarigivir soproxilTenofovir Disoproxil Fumarate
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSpring Bank
China Registration ClassN/A

Develop Information

Active CompaniesSpring Bank
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A